MedTrace Logo

Convalescent Plasma for COVID-19

NCT04365439 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-03-29

No results posted yet for this study

Summary

The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess:

* the titer of anti-COVID-19 antibodies in the donors and in the patients before and after treatment;
* the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment;
* the impact of plasma transfusion on the reduction of viral load and inflammation
* safety and tolerability
* clinical efficacy

Conditions

  • Blood Plasma Therapy
  • COVID

Interventions

BIOLOGICAL

Blood plasma

Convalescent plasma after COVID-19

Sponsors & Collaborators

  • Enos Bernasconi

    lead OTHER

Principal Investigators

  • Stefano Fontana, M.D. · Servizio Trasfusionale, Lugano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2020-12-20
Completion
2021-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365439 on ClinicalTrials.gov